27 March 2024
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT"
or the "Company")
New Agreement for Lease at Oxford
Technology Park
Innovation Quarter Letting to Coldquanta
UK Limited
Life Science REIT (LSE: LABS), the real estate
investment trust focused on UK life sciences properties, is pleased
to announce an Agreement for Lease of 7,497 sq. ft. of fully fitted
space at the Innovation Quarter ("IQ") at Oxford Technology Park
("OTP") to Coldquanta UK Limited ("ColdQuanta"), part of
Infleqtion, a global quantum technology company. The lease will
complete once the laboratory fitout works are complete.
ColdQuanta uses atomic physics to build quantum
computers and to integrate them across networks, delivering an
ecosystem of devices and platforms. This next generation of
computing power has the potential to transform the life science
industry by significantly reducing drug development time and costs
and demonstrates the growing interdependence between technology and
life sciences.
ColdQuanta will pay an annual rent of £337,365,
equating to £45.0 psf for ten years, with a break clause and rent
review at the end of the fifth year. This is a significant premium
to other lettings achieved at the IQ and reflects the fact that
Life Science REIT is fully fitting out the space.
The IQ is a differentiated offer providing
smaller, more flexible space at OTP. Covering 69,700 sq. ft., the
IQ reached practical completion in August last year; it is EPC A
rated and is on track to achieve a BREEAM Excellent
certification.
Ian Harris,
Director of Asset Management at Ironstone Asset Management, the
Company's Investment Adviser, said: "We are
really encouraged by the leasing momentum we are seeing at the IQ,
strengthening our conviction in this more flexible format and the
fully fitted proposition. The IQ also provides emerging life
sciences businesses with the opportunity to grow and collaborate
with like-minded businesses at OTP, in neighbouring Begbroke and
the academic institutions in Oxford."
OTP was acquired by Life Science REIT in May
2022. It now comprises six completed buildings totalling 231,600
sq. ft. and 266,100 sq. ft. of development space. Existing
occupiers at the park include The Native Antigen Company, a
developer and manufacturer of antigens and antibodies, Oxford Gene
Technology, a provider of clinical research and diagnostic
solutions, and Oxford Ionics, a leading quantum computing
business.
END
Enquiries:
Ironstone Asset Management - Investment
Adviser
|
+44 20 3011 2160
|
Simon Farnsworth, Managing
Director
Simon.farnsworth@ironstoneam.com
|
|
Joanna Waddingham, Head of Investor
Relations and Corporate Affairs
|
|
Joanna.Waddingham@ironstoneam.com
|
|
|
|
Link Company Matters Limited - Company
Secretary
|
|
labs_cosec@linkgroup.co.uk
|
|
|
|
Panmure Gordon (UK) Limited - Joint Corporate
Broker
|
+44 20 7886 2500
|
Alex Collins / Tom
Scrivens
|
|
|
|
Jefferies International Limited - Joint Corporate
Broker
|
+44 20 7029 8000
|
Tom Yeadon / Oliver
Nott
|
|
G10
Capital Limited - AIFM
|
+44 20 7397 5450
|
Maria Baldwin
|
|
Buchanan - Financial PR
|
+44 20 7466 5000
|
Mark Court / Henry Wilson / Verity
Parker
|
|
LifeSciencereit@buchanan.uk.com
|
|
Notes to editors
Life Science REIT plc is a specialist
property business focused on the UK's growing life science sector.
The Company's portfolio of assets is located across the "Golden
Triangle" of research and development hubs in Oxford, Cambridge and
London's Knowledge Quarter and its strategic vision is to become
the property provider of choice for life science companies in the
UK.
Life Science REIT is addressing the
acute demand-supply imbalance for laboratory space in the "Golden
Triangle", which is characterised by low vacancy rates and prime
rental increases. The UK life science sector itself is underpinned
by strong structural drivers, including an ageing population and a
supportive regulatory environment as well as the growing
interdependence with technology, which is expanding the life
science spectrum, driving strong demand for laboratory
space.
The Company's diverse portfolio of
assets ranges from a 20-acre science park currently under
development through to fully let buildings, with an important part
of the Company's strategy being the conversion of existing
properties to laboratory space.
The Company's investment policy is
focused on capital growth whilst also providing a growing level of
income.
Life Science REIT trades on the Main
Market of the London Stock Exchange under the ticker
LABS.
Further information is available
at https://lifesciencereit.co.uk.
To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.